[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U/M (underspecified leading to multiple defensible answers).\\nVerdict on keyed answer: Not uniquely determinable; E is defensible but not clearly best.\\nKey stem clues: Massive variceal upper GI bleed in alcoholic cirrhosis, refractory to endoscopy and octreotide; hemodynamic instability; TIPS considered but an unspecified “rare anatomical variant” precludes it.\\nIssues: The nature of the anatomic variant is not described; it is unclear why standard TIPS cannot be modified (e.g., alternative access). After failed endoscopy and pharmacotherapy with ongoing instability, evidence-based options include temporary balloon tamponade (B) as a bridge and rescue TIPS or other radiologic/surgical options. Angiographic embolization (E) of the coronary/left gastric vein is plausible but not clearly more appropriate than balloon tamponade in an actively exsanguinating, unstable patient, and “coronary vein embolization” is not a standard, widely taught next-step label. Thus more than one option is reasonably defensible.\\nMedical accuracy: Overall concept of radiologic rescue when TIPS is not feasible is reasonable, but terminology and hierarchy of steps vs temporizing measures lack nuance.\\nMinimal fix: Specify that the patient is currently stabilized on maximal resuscitation and balloon tamponade is unavailable/contraindicated, and clarify that angiography shows active bleeding from the coronary vein suitable for embolization.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U/M (underspecified leading to multiple defensible answers).\nVerdict on keyed answer: Not uniquely determinable; E is defensible but not clearly best.\nKey stem clues: Massive variceal upper GI bleed in alcoholic cirrhosis, refractory to endoscopy and octreotide; hemodynamic instability; TIPS considered but an unspecified “rare anatomical variant” precludes it.\nIssues: The nature of the anatomic variant is not described; it is unclear why standard TIPS cannot be modified (e.g., alternative access). After failed endoscopy and pharmacotherapy with ongoing instability, evidence-based options include temporary balloon tamponade (B) as a bridge and rescue TIPS or other radiologic/surgical options. Angiographic embolization (E) of the coronary/left gastric vein is plausible but not clearly more appropriate than balloon tamponade in an actively exsanguinating, unstable patient, and “coronary vein embolization” is not a standard, widely taught next-step label. Thus more than one option is reasonably defensible.\nMedical accuracy: Overall concept of radiologic rescue when TIPS is not feasible is reasonable, but terminology and hierarchy of steps vs temporizing measures lack nuance.\nMinimal fix: Specify that the patient is currently stabilized on maximal resuscitation and balloon tamponade is unavailable/contraindicated, and clarify that angiography shows active bleeding from the coronary vein suitable for embolization.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: metastatic breast cancer; on paclitaxel; acute dyspnea and hypoxemia; CT angiography negative for PE; echocardiography shows right ventricular strain (suggesting pulmonary hypertension/acute pulmonary vascular obstruction); bone marrow biopsy confirms tumor infiltration. The explanation asserts tumor microembolism to pulmonary vasculature.\\n\\nProblem: Option B (“Tumor microembolism syndrome”) and option E (“Metastatic tumor thrombus in pulmonary arteries”) are not clearly differentiable based on the given data. Both describe tumor cells in pulmonary arterial circulation causing PH/RV strain; no imaging description (e.g., perfusion defects vs visible filling defects vs microvascular-only disease) is provided to distinguish microemboli from larger macroscopic tumor thrombi. Bone marrow infiltration shows disseminated disease but does not favor B over E. Thus more than one answer is medically defensible.\\n\\nMedical accuracy: The characterizations of B, C, and D are appropriate and largely consistent with current knowledge; paclitaxel pneumonitis usually presents with parenchymal changes.\\n\\nMinimal fix: Add a statement indicating that CT angiography and conventional imaging show no visible intraluminal filling defects, with only subtle perfusion mismatch suggestive of microvascular obstruction, and/or reword option E to specify “large macroscopic intraluminal tumor thrombus visible on CT angiography.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: metastatic breast cancer; on paclitaxel; acute dyspnea and hypoxemia; CT angiography negative for PE; echocardiography shows right ventricular strain (suggesting pulmonary hypertension/acute pulmonary vascular obstruction); bone marrow biopsy confirms tumor infiltration. The explanation asserts tumor microembolism to pulmonary vasculature.\n\nProblem: Option B (“Tumor microembolism syndrome”) and option E (“Metastatic tumor thrombus in pulmonary arteries”) are not clearly differentiable based on the given data. Both describe tumor cells in pulmonary arterial circulation causing PH/RV strain; no imaging description (e.g., perfusion defects vs visible filling defects vs microvascular-only disease) is provided to distinguish microemboli from larger macroscopic tumor thrombi. Bone marrow infiltration shows disseminated disease but does not favor B over E. Thus more than one answer is medically defensible.\n\nMedical accuracy: The characterizations of B, C, and D are appropriate and largely consistent with current knowledge; paclitaxel pneumonitis usually presents with parenchymal changes.\n\nMinimal fix: Add a statement indicating that CT angiography and conventional imaging show no visible intraluminal filling defects, with only subtle perfusion mismatch suggestive of microvascular obstruction, and/or reword option E to specify “large macroscopic intraluminal tumor thrombus visible on CT angiography.”", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young adult with severe headache, vomiting, photophobia after hiking; CSF shows lymphocytic pleocytosis, elevated protein, normal glucose (typical of viral meningitis/encephalitis rather than bacterial); PCR for common viruses is negative; serology positive for a rare pathogen (implies identified viral/arboviral etiology without specific therapy). These point to a confirmed non-herpes, non-bacterial, non-fungal viral CNS infection for which no targeted treatment exists; thus supportive care with monitoring is appropriate initial management.\\nOption analysis: Acyclovir (A) is for suspected HSV encephalitis, but negative PCR for common viruses and serologic confirmation of a different rare pathogen argue against continuing empiric acyclovir as the “most appropriate” initial management in this question’s framing. Empiric antibiotics (B) are inconsistent with the viral CSF profile and established alternative diagnosis. Corticosteroids (D) are not standard first-line in uncomplicated viral meningitis. Antifungals (E) are inappropriate given CSF pattern and identified non-fungal pathogen. No major medical inaccuracies.\\nMinimal fix: Explicitly name the rare arbovirus in the stem to avoid ambiguity about availability of specific therapy and solidify rationale for purely supportive care.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young adult with severe headache, vomiting, photophobia after hiking; CSF shows lymphocytic pleocytosis, elevated protein, normal glucose (typical of viral meningitis/encephalitis rather than bacterial); PCR for common viruses is negative; serology positive for a rare pathogen (implies identified viral/arboviral etiology without specific therapy). These point to a confirmed non-herpes, non-bacterial, non-fungal viral CNS infection for which no targeted treatment exists; thus supportive care with monitoring is appropriate initial management.\nOption analysis: Acyclovir (A) is for suspected HSV encephalitis, but negative PCR for common viruses and serologic confirmation of a different rare pathogen argue against continuing empiric acyclovir as the “most appropriate” initial management in this question’s framing. Empiric antibiotics (B) are inconsistent with the viral CSF profile and established alternative diagnosis. Corticosteroids (D) are not standard first-line in uncomplicated viral meningitis. Antifungals (E) are inappropriate given CSF pattern and identified non-fungal pathogen. No major medical inaccuracies.\nMinimal fix: Explicitly name the rare arbovirus in the stem to avoid ambiguity about availability of specific therapy and solidify rationale for purely supportive care.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U/M (underspecified leading to multiple defensible answers)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 7-year-old with autism, recurrent staring spells and facial twitching, EEG with multifocal epileptiform discharges, MRI cortical dysplasia, de novo mutation, question asks for “most effective first-line therapy.” Explanation implicitly assumes a specific channelopathy (SCN8A) and focuses on behavioral side effects in autism.\\nMain logical issues: The stem never specifies SCN8A or any particular genetic epilepsy syndrome; it just mentions a generic de novo mutation. For a child with multifocal epileptiform discharges and cortical dysplasia, valproic acid as a broad-spectrum agent (A) and levetiracetam (B) are both widely used first-line; evidence that levetiracetam is clearly superior or behaviorally better in autism is not firmly established, and levetiracetam itself can provoke behavioral problems. Thus more than one option is defensible and the keyed choice depends on an unstated assumption about the mutation type and drug-behavior profile.\\nMain medical accuracy issues: The rationale overstates a consensus preference for levetiracetam in “mutations like SCN8A” and for autism-related behavioral safety.\\nMinimal fix: Explicitly specify an SCN8A-related epileptic encephalopathy with prior behavioral worsening on valproate, or reframe to ask which agent best minimizes behavioral adverse effects.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U/M (underspecified leading to multiple defensible answers)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 7-year-old with autism, recurrent staring spells and facial twitching, EEG with multifocal epileptiform discharges, MRI cortical dysplasia, de novo mutation, question asks for “most effective first-line therapy.” Explanation implicitly assumes a specific channelopathy (SCN8A) and focuses on behavioral side effects in autism.\nMain logical issues: The stem never specifies SCN8A or any particular genetic epilepsy syndrome; it just mentions a generic de novo mutation. For a child with multifocal epileptiform discharges and cortical dysplasia, valproic acid as a broad-spectrum agent (A) and levetiracetam (B) are both widely used first-line; evidence that levetiracetam is clearly superior or behaviorally better in autism is not firmly established, and levetiracetam itself can provoke behavioral problems. Thus more than one option is defensible and the keyed choice depends on an unstated assumption about the mutation type and drug-behavior profile.\nMain medical accuracy issues: The rationale overstates a consensus preference for levetiracetam in “mutations like SCN8A” and for autism-related behavioral safety.\nMinimal fix: Explicitly specify an SCN8A-related epileptic encephalopathy with prior behavioral worsening on valproate, or reframe to ask which agent best minimizes behavioral adverse effects.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers, with elements of U)\\nVerdict on keyed answer: Not uniquely determinable; C is plausible but not clearly the single best answer.\\n\\nKey stem clues: 55-year-old man, sudden dysarthria and hemiparesis; MRI: acute infarct in lenticulostriate territory (classically a deep perforator/lacunar territory); vessel imaging normal; coagulation studies reveal an abnormality. The question asks for the underlying mechanism.\\n\\nProblems: Lenticulostriate territory plus normal large-vessel imaging strongly supports a lacunar infarct due to small vessel lipohyalinosis (choice B). The stem does not specify what the coagulation abnormality is; without naming antiphospholipid antibodies, lupus anticoagulant, or similar, multiple mechanisms remain plausible. A generic “coagulation abnormality” could reflect many conditions, including incidental lab findings not causative. Thus both B (based on territory and imaging) and C (based on vague “coagulation abnormality”) are defensible.\\n\\nMedical accuracy: The explanation’s claim that “lacunar infarcts are typically hypertensive, not matching this profile” is weak; many lacunes occur in older patients with vascular risk regardless of explicit hypertension in the stem.\\n\\nMinimal fix: Specify the coagulation abnormality as positive antiphospholipid antibodies (e.g., lupus anticoagulant) and/or remove “lenticulostriate territory” or label infarct as cortical to clearly favor C over B.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers, with elements of U)\nVerdict on keyed answer: Not uniquely determinable; C is plausible but not clearly the single best answer.\n\nKey stem clues: 55-year-old man, sudden dysarthria and hemiparesis; MRI: acute infarct in lenticulostriate territory (classically a deep perforator/lacunar territory); vessel imaging normal; coagulation studies reveal an abnormality. The question asks for the underlying mechanism.\n\nProblems: Lenticulostriate territory plus normal large-vessel imaging strongly supports a lacunar infarct due to small vessel lipohyalinosis (choice B). The stem does not specify what the coagulation abnormality is; without naming antiphospholipid antibodies, lupus anticoagulant, or similar, multiple mechanisms remain plausible. A generic “coagulation abnormality” could reflect many conditions, including incidental lab findings not causative. Thus both B (based on territory and imaging) and C (based on vague “coagulation abnormality”) are defensible.\n\nMedical accuracy: The explanation’s claim that “lacunar infarcts are typically hypertensive, not matching this profile” is weak; many lacunes occur in older patients with vascular risk regardless of explicit hypertension in the stem.\n\nMinimal fix: Specify the coagulation abnormality as positive antiphospholipid antibodies (e.g., lupus anticoagulant) and/or remove “lenticulostriate territory” or label infarct as cortical to clearly favor C over B.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – D is not the best answer; A is better supported.\\nKey stem clues: Elderly ICU patient with septic shock, persistent hypotension despite fluids and vasopressors; adrenal function testing shows **blunted cortisol response** with **normal random cortisol**. That wording implies a cosyntropin (ACTH) stimulation test has already been done and is abnormal (“critical illness–related corticosteroid insufficiency,” CIRCI).\\nGiven persistent shock and evidence of inadequate adrenal response, current sepsis/critical care practice supports **stress-dose hydrocortisone** for vasopressor-refractory septic shock with blunted response, regardless of baseline cortisol. Thus A is the most defensible next step.\\nOption D (switch to vasopressin) is reasonable in septic shock, but the question explicitly foregrounds adrenal testing abnormalities and asks for the “next step in management” in that context; nothing indicates vasopressin hasn’t already been tried or that steroids are contraindicated.\\nMedical accuracy: The explanation’s statement that patients with blunted response “may not respond to steroids if cortisol is normal” conflicts with consensus use of hydrocortisone in CIRCI.\\nMinimal fix: Change the keyed answer and explanation to A (initiate hydrocortisone) or alter the stem to show normal ACTH test and no evidence of CIRCI if D is desired.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – D is not the best answer; A is better supported.\nKey stem clues: Elderly ICU patient with septic shock, persistent hypotension despite fluids and vasopressors; adrenal function testing shows **blunted cortisol response** with **normal random cortisol**. That wording implies a cosyntropin (ACTH) stimulation test has already been done and is abnormal (“critical illness–related corticosteroid insufficiency,” CIRCI).\nGiven persistent shock and evidence of inadequate adrenal response, current sepsis/critical care practice supports **stress-dose hydrocortisone** for vasopressor-refractory septic shock with blunted response, regardless of baseline cortisol. Thus A is the most defensible next step.\nOption D (switch to vasopressin) is reasonable in septic shock, but the question explicitly foregrounds adrenal testing abnormalities and asks for the “next step in management” in that context; nothing indicates vasopressin hasn’t already been tried or that steroids are contraindicated.\nMedical accuracy: The explanation’s statement that patients with blunted response “may not respond to steroids if cortisol is normal” conflicts with consensus use of hydrocortisone in CIRCI.\nMinimal fix: Change the keyed answer and explanation to A (initiate hydrocortisone) or alter the stem to show normal ACTH test and no evidence of CIRCI if D is desired.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified, leading toward M)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 38-year-old with CML on dasatinib, develops pleural effusions (known dasatinib toxicity) and fatigue; cytogenetics show “additional clonal evolution.” Question: “most appropriate therapeutic adjustment.” Keyed to ponatinib, with rationale assuming T315I mutation.\\nMain logical issues: The stem never states the specific mutation (e.g., T315I). “Clonal evolution” alone does not equal T315I; it usually implies disease progression to more advanced phase, but management depends on the precise resistance mutation and disease phase. Without mutation data, multiple options are defendable: (1) ponatinib for suspected resistant mutation, but carries vascular/pulmonary risk; (2) allogeneic stem cell transplant is reasonable in a young patient with clonal evolution/progression on second-generation TKI; (3) simply dose-reducing dasatinib is inappropriate given clonal evolution, but the item doesn’t explicitly say progression vs isolated toxicity. Thus the keyed answer relies on an unstated assumption (presence of T315I), making the item underspecified and bordering on multiple defensible answers.\\nMain medical accuracy issues: Equating clonal evolution on dasatinib with T315I is inaccurate.\\nMinimal fix: Explicitly state “BCR-ABL mutation analysis reveals a T315I mutation” to justify ponatinib as single best answer (or alternatively specify advanced-phase progression to justify transplant vs ponatinib distinction).\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified, leading toward M)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 38-year-old with CML on dasatinib, develops pleural effusions (known dasatinib toxicity) and fatigue; cytogenetics show “additional clonal evolution.” Question: “most appropriate therapeutic adjustment.” Keyed to ponatinib, with rationale assuming T315I mutation.\nMain logical issues: The stem never states the specific mutation (e.g., T315I). “Clonal evolution” alone does not equal T315I; it usually implies disease progression to more advanced phase, but management depends on the precise resistance mutation and disease phase. Without mutation data, multiple options are defendable: (1) ponatinib for suspected resistant mutation, but carries vascular/pulmonary risk; (2) allogeneic stem cell transplant is reasonable in a young patient with clonal evolution/progression on second-generation TKI; (3) simply dose-reducing dasatinib is inappropriate given clonal evolution, but the item doesn’t explicitly say progression vs isolated toxicity. Thus the keyed answer relies on an unstated assumption (presence of T315I), making the item underspecified and bordering on multiple defensible answers.\nMain medical accuracy issues: Equating clonal evolution on dasatinib with T315I is inaccurate.\nMinimal fix: Explicitly state “BCR-ABL mutation analysis reveals a T315I mutation” to justify ponatinib as single best answer (or alternatively specify advanced-phase progression to justify transplant vs ponatinib distinction).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: acute collapse after unknown ingestion; classic cholinergic findings (bradycardia, hypotension, miosis); partial, transient response to atropine with recurrence of symptoms. This pattern is typical of significant organophosphate exposure, in which muscarinic signs improve with atropine but recur due to continued AChE inhibition, requiring an oxime (pralidoxime) to regenerate acetylcholinesterase.\\nEvaluation of alternatives: N-acetylcysteine (B) is specific for acetaminophen hepatotoxicity, which does not present with a cholinergic toxidrome. Flumazenil (C) is for benzodiazepine overdose (CNS depression, normal pupils, usually tachy/bradycardia not cholinergic signs) and is generally avoided due to seizure risk. Physostigmine (D) increases ACh and is used in severe anticholinergic toxicity—the opposite toxidrome here. Hydroxocobalamin (E) treats cyanide poisoning, which presents with lactic acidosis and cardiovascular collapse but not bradycardia/miosis responsive to atropine.\\nMain medical accuracy issues: None significant; presentation and management are consistent with standard toxicology teaching.\\nMinimal fix: Add one more cholinergic sign (e.g., diaphoresis or bronchorrhea) or specify recent pesticide exposure to make organophosphate poisoning even more explicit without changing the key.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: acute collapse after unknown ingestion; classic cholinergic findings (bradycardia, hypotension, miosis); partial, transient response to atropine with recurrence of symptoms. This pattern is typical of significant organophosphate exposure, in which muscarinic signs improve with atropine but recur due to continued AChE inhibition, requiring an oxime (pralidoxime) to regenerate acetylcholinesterase.\nEvaluation of alternatives: N-acetylcysteine (B) is specific for acetaminophen hepatotoxicity, which does not present with a cholinergic toxidrome. Flumazenil (C) is for benzodiazepine overdose (CNS depression, normal pupils, usually tachy/bradycardia not cholinergic signs) and is generally avoided due to seizure risk. Physostigmine (D) increases ACh and is used in severe anticholinergic toxicity—the opposite toxidrome here. Hydroxocobalamin (E) treats cyanide poisoning, which presents with lactic acidosis and cardiovascular collapse but not bradycardia/miosis responsive to atropine.\nMain medical accuracy issues: None significant; presentation and management are consistent with standard toxicology teaching.\nMinimal fix: Add one more cholinergic sign (e.g., diaphoresis or bronchorrhea) or specify recent pesticide exposure to make organophosphate poisoning even more explicit without changing the key.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 12-year-old with JIA on etanercept (TNF inhibitor), now with fever, rash, lymphadenopathy; viral serology positive but lymph node PCR shows a clonal T‑cell population. The question asks for the most likely complication explaining these findings. A clonal T‑cell population in a patient on a TNF inhibitor strongly suggests TNF inhibitor–associated T‑cell lymphoma. EBV-associated lymphoproliferative disorder is typically B‑cell and would not emphasize clonal T‑cell population; the explanation correctly notes that. MAS and secondary HLH are cytokine-driven, reactive syndromes without a clonal lymphoid population, so clonality argues against them. DRESS would usually involve eosinophilia and drug rash, not clonal T‑cells on node biopsy.\\nMain logical issues: None significant; stem sufficiently directs to lymphoma related to TNF inhibitor, and choices are mutually distinguishable.\\nMain medical accuracy issues: Minor—EBV-LPD can have T/NK variants, but in this context the B‑cell predominance point is reasonable for board level.\\nMinimal fix: Explicitly state that the lymph node shows a clonal T-cell lymphoma to remove any residual ambiguity about reactive vs malignant process.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 12-year-old with JIA on etanercept (TNF inhibitor), now with fever, rash, lymphadenopathy; viral serology positive but lymph node PCR shows a clonal T‑cell population. The question asks for the most likely complication explaining these findings. A clonal T‑cell population in a patient on a TNF inhibitor strongly suggests TNF inhibitor–associated T‑cell lymphoma. EBV-associated lymphoproliferative disorder is typically B‑cell and would not emphasize clonal T‑cell population; the explanation correctly notes that. MAS and secondary HLH are cytokine-driven, reactive syndromes without a clonal lymphoid population, so clonality argues against them. DRESS would usually involve eosinophilia and drug rash, not clonal T‑cells on node biopsy.\nMain logical issues: None significant; stem sufficiently directs to lymphoma related to TNF inhibitor, and choices are mutually distinguishable.\nMain medical accuracy issues: Minor—EBV-LPD can have T/NK variants, but in this context the B‑cell predominance point is reasonable for board level.\nMinimal fix: Explicitly state that the lymph node shows a clonal T-cell lymphoma to remove any residual ambiguity about reactive vs malignant process.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed)\\nVerdict on keyed answer: Miskeyed — A is the best-supported answer, not B.\\n\\nKey stem clues: 68-year-old man with established ALS, progressive dysphagia and aspiration, videofluoroscopy showing *pharyngeal weakness*, already on non-invasive ventilation. There is no mention of cricopharyngeal achalasia/outlet obstruction or upper esophageal sphincter failure; instead, global pharyngeal weakness suggests bulbar muscle involvement with high aspiration risk and poor airway protection.\\n\\nGiven ALS progression and aspiration, the standard next step is securing enteral nutrition while minimizing aspiration risk, typically via percutaneous endoscopic gastrostomy (PEG). Botulinum toxin to cricopharyngeus is indicated for cricopharyngeal spasm/achalasia, which is not described here and could worsen aspiration in pharyngeal weakness. Tracheostomy is mainly for ventilation, which is already supported noninvasively, and does not directly fix swallowing. Speech therapy alone is insufficient for “progressive dysphagia and aspiration” in advanced ALS. Edrophonium is irrelevant.\\n\\nMain medical accuracy issue: Explanation incorrectly assumes cricopharyngeal dysfunction; stem specifies pharyngeal weakness, making B inappropriate.\\n\\nMinimal fix: Either change stem to specify “cricopharyngeal achalasia/outlet obstruction” on VFSS, or change the keyed answer to A (PEG placement) and adjust explanation accordingly.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed)\nVerdict on keyed answer: Miskeyed — A is the best-supported answer, not B.\n\nKey stem clues: 68-year-old man with established ALS, progressive dysphagia and aspiration, videofluoroscopy showing *pharyngeal weakness*, already on non-invasive ventilation. There is no mention of cricopharyngeal achalasia/outlet obstruction or upper esophageal sphincter failure; instead, global pharyngeal weakness suggests bulbar muscle involvement with high aspiration risk and poor airway protection.\n\nGiven ALS progression and aspiration, the standard next step is securing enteral nutrition while minimizing aspiration risk, typically via percutaneous endoscopic gastrostomy (PEG). Botulinum toxin to cricopharyngeus is indicated for cricopharyngeal spasm/achalasia, which is not described here and could worsen aspiration in pharyngeal weakness. Tracheostomy is mainly for ventilation, which is already supported noninvasively, and does not directly fix swallowing. Speech therapy alone is insufficient for “progressive dysphagia and aspiration” in advanced ALS. Edrophonium is irrelevant.\n\nMain medical accuracy issue: Explanation incorrectly assumes cricopharyngeal dysfunction; stem specifies pharyngeal weakness, making B inappropriate.\n\nMinimal fix: Either change stem to specify “cricopharyngeal achalasia/outlet obstruction” on VFSS, or change the keyed answer to A (PEG placement) and adjust explanation accordingly.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]